Gaurav Sharma1, Christine G Lian2, William M Lin2, Ali Amin-Mansour3, Judit Jané-Valbuena3, Levi Garraway3, Wendi Bao1, Charles H Yoon4, Nageatte Ibrahim1. 1. Division of Surgical Oncology, Department of Surgery, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA. 2. Program of Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 3. Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University, Cambridge, MA, USA. 4. Division of Surgical Oncology, Department of Surgery, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA. chyoon@partners.org.
Abstract
BACKGROUND: There is limited knowledge of the genetic alterations in acral melanoma metastases at different anatomic sites. Here, we characterized the genetic abnormalities of metastases in a 51-year-old man with stage IIIC heel melanoma who developed concomitant brain and cutaneous metastases in spite of multiple treatment modalities. METHODS: Melanoma cells were isolated following palliative resection of the patient's cortical tumor and biopsy of cutaneous thigh metastasis. Mutational analysis using polymerase chain reaction amplification and BLAST, as well as exome sequencing (160 Mb coverage) was performed on the tumors, cell lines generated thereof and normal lymph nodes. RESULTS: All specimens had neuroblastoma RAS viral oncogene homolog Q61K mutations. There was a 40-fold higher somatic mutation frequency in the brain metastasis compared to the cutaneous metastasis. The former showed truncations of DNA mismatch repair genes (MLH1 and MSH2), and non-canonical BRAF (v-raf murine sarcoma viral oncogene homolog B1), PIK3CA and NF-1 mutations not observed in the extracranial lesion. Genomic profiling of each cell line was concordant with the respective original tumor tissue. CONCLUSIONS: We present the mutational differences between brain and cutaneous acral melanoma metastases in a patient with concomitant lesions. Further genetic and functional studies are needed to understand the biology of metastatic disease appearing at different sites.
BACKGROUND: There is limited knowledge of the genetic alterations in acral melanoma metastases at different anatomic sites. Here, we characterized the genetic abnormalities of metastases in a 51-year-old man with stage IIIC heel melanoma who developed concomitant brain and cutaneous metastases in spite of multiple treatment modalities. METHODS:Melanoma cells were isolated following palliative resection of the patient's cortical tumor and biopsy of cutaneous thigh metastasis. Mutational analysis using polymerase chain reaction amplification and BLAST, as well as exome sequencing (160 Mb coverage) was performed on the tumors, cell lines generated thereof and normal lymph nodes. RESULTS: All specimens had neuroblastoma RAS viral oncogene homolog Q61K mutations. There was a 40-fold higher somatic mutation frequency in the brain metastasis compared to the cutaneous metastasis. The former showed truncations of DNA mismatch repair genes (MLH1 and MSH2), and non-canonical BRAF (v-raf murine sarcoma viral oncogene homolog B1), PIK3CA and NF-1 mutations not observed in the extracranial lesion. Genomic profiling of each cell line was concordant with the respective original tumor tissue. CONCLUSIONS: We present the mutational differences between brain and cutaneous acral melanoma metastases in a patient with concomitant lesions. Further genetic and functional studies are needed to understand the biology of metastatic disease appearing at different sites.
Authors: Paul W Sperduto; Brian Berkey; Laurie E Gaspar; Minesh Mehta; Walter Curran Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-10 Impact factor: 7.038
Authors: John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian Journal: N Engl J Med Date: 2005-11-17 Impact factor: 91.245
Authors: William M Lin; Alissa C Baker; Rameen Beroukhim; Wendy Winckler; Whei Feng; Jennifer M Marmion; Elisabeth Laine; Heidi Greulich; Hsiuyi Tseng; Casey Gates; F Stephen Hodi; Glenn Dranoff; William R Sellers; Roman K Thomas; Matthew Meyerson; Todd R Golub; Reinhard Dummer; Meenhard Herlyn; Gad Getz; Levi A Garraway Journal: Cancer Res Date: 2008-02-01 Impact factor: 12.701
Authors: Alvin P Makohon-Moore; Evan J Lipson; Jody E Hooper; Amanda Zucker; Jungeui Hong; Craig M Bielski; Akimasa Hayashi; Collin Tokheim; Priscilla Baez; Rajya Kappagantula; Zachary Kohutek; Vladimir Makarov; Nadeem Riaz; Michael A Postow; Paul B Chapman; Rachel Karchin; Nicholas D Socci; David B Solit; Timothy A Chan; Barry S Taylor; Suzanne L Topalian; Christine A Iacobuzio-Donahue Journal: Clin Cancer Res Date: 2020-12-15 Impact factor: 13.801